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Abstract
Oral delivery of therapeutics is the preferred route for systemic drug administration due to ease of
access and improved patient compliance. However, many therapeutics suffer from low oral bioa-
vailability due to low pH and enzymatic conditions, poor cellular permeability, and low residence
time. Microfabrication techniques have been used to create planar, asymmetric microdevices for
oral drug delivery to address these limitations. The geometry of these microdevices facilitates pro-
longed drug exposure with unidirectional release of drug toward gastrointestinal epithelium. While
these devices have significantly enhanced drug permeability in vitro and in vivo, loading drug into
the micron-scale reservoirs of the devices in a low-waste, high-capacity manner remains challeng-
ing. Here, we use picoliter-volume inkjet printing to load topotecan and insulin into planar
microdevices efficiently. Following a simple surface functionalization step, drug solution can be
spotted into the microdevice reservoir. We show that relatively high capacities of both topotecan
and insulin can be loaded into microdevices in a rapid, automated process with little to no drug
waste.
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1 | INTRODUCTION
Oral drug administration is less invasive and has better patient
compliance than parenteral methods making it the preferred route
for both patients and physicians. However, there are significant
physiological barriers present in the gastrointestinal (GI) tract, which
lower the bioavailability of many drugs. The low pH of the stom-
ach and intestinal digestive enzymes cause drug breakdown before
absorption.1,2 Furthermore, many drugs possess low solubility and/
or low permeation through the epithelial mucosa of the small intes-
tine, further reducing bioavailability of many drugs. Thus, the vast
majority of biological therapeutics currently require parenteral
administration due to their high molecular weights and low
stability.3
Over the past decade, patches, hydrogels, and microparticles and
nanoparticles have been explored as oral drug carriers.4–6 However,
issues with polydispersity and drug dosing have limited the translation
of these delivery methods. Previous work in our lab has demonstrated
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that polymeric, micron-scale planar devices, henceforth referred to as
microdevices, are capable of enhanced adhesion in the GI tract due to
their high surface-area-to-mass ratio and flat shape that minimizes the
amount of shear stress from intestinal fluid flow.7 Additionally, a drug
reservoir can be fabricated on one side of the disc-shaped microdevice
to further improve drug bioavailability by providing unidirectional
release rather than the omnidirectional release of drug from conven-
tional microparticles. The presence of a reservoir can protect drug pay-
loads from the harsh microenvironment of the GI tract until release is
desired. The benefits of microdevice delivery have been previously
demonstrated in vivo with acyclovir where the bioavailability was
observed to be 4.5-fold higher in mice when administered in microde-
vices relative to a bolus dose of oral solution.8 These devices can be
manufactured en masse in a reproducible manner by taking advantage
of well-established microfabrication techniques. The advantages of
microdevices make this technology an attractive candidate for oral
drug delivery of pharmaceuticals.
While microdevices are a promising technology, loading drug into
the micron-scale reservoirs of these devices in an efficient manner
remains challenging. Traditional oral dosage requires large amounts of
drug, which can be cost prohibitive. Previously, microdevices have
been loaded by spin-casting a drug-hydrogel solution over the microde-
vices and then selectively cross-linking the solution within device reser-
voirs by ultraviolet light (UV) exposure.8 However, drug loading
efficiency is decreased due to losses during the spin-casting step, and
the volume occupied by the hydrogel reduces the drug capacity of the
devices. Furthermore, UV light can damage photosensitive molecules
and lead to degradation of the active compound. More recently, Fox
et al. demonstrated the use of nanostraw membranes in order to pas-
sively take up drug into microdevice reservoirs via diffusion.9 Unfortu-
nately, this method requires the use of concentrated drug solution that
is usually discarded after loading, thus leading to waste, and drug load-
ing capacity is limited to the product of the drug solubility and microde-
vice reservoir volume. Therefore, alternative loading methods need to
be considered.
Inkjet printing is a technique that has been used for microarray
spotting, surface functionalization, cell culturing, and drug
formulation.10–13 A major advantage of inkjet printing is its drop-on-
demand mode, which allows for spotting of precise volumes of liquid
onto a surface. Previously, it has been shown that small-volume dis-
pensing systems can be used to print polymer solutions into microscale
containers.14,15 When printing drugs, the solutions ideally would not
contain polymer to maximize the free volume available for drug. These
previous methods were used for tall microcontainers measuring over
250 mm in height with aspect ratios typically >1.14,15 However, planar
microdevices for oral drug delivery are typically designed with heights
<10 lm and aspect ratios <0.1.9,16 To our knowledge, this method has
not been used with thin (<10 mm thickness) microdevices, which typi-
cally have reservoir volumes in the tens of pL range rather than the
500 pL volume reservoirs previously utilized for inkjet printing.7,14
In this study, we demonstrate the use of picoliter-volume inkjet
printing to efficiently load planar microdevices with topotecan, a small
molecule chemotherapeutic agent, and insulin, a peptide hormone.
Both drug solutions were prepared in acidic solutions and were directly
spotted into the reservoirs of each microdevice with high precision and
accuracy in an automated fashion. We also introduce a simple surface
modification step to improve the surface hydrophobicity of the micro-
devices, ensuring reservoir loading without overflow. We demonstrate
that microdevices that can be loaded with nearly 100% of the free total
volume space filled with both small molecule and biological therapeu-
tics in an essentially zero-waste manner.
2 | MATERIALS AND METHODS
2.1 | Materials for device fabrication and drug loading
Topotecan hydrochloride, insulin (recombinant human), hydrochloric
acid (HCl), and trichloro(1H,1H,2H,2H-perfluorooctyl)silane were pur-
chased from Sigma-Aldrich, USA. Poly(methyl methacrylate) (950 kDa
in anisole), Shipley 1818 positive photoresist, Microposit 351 devel-
oper, and 1112A photoresist remover were purchased from Micro-
Chem, USA. CyQUANT direct cell proliferation assay kit was purchased
from Thermo Fisher Scientific, USA. Silicon wafers were purchased
from Addison Engineering Inc, USA.
2.2 | Microdevice fabrication
Microdevices with reservoirs were fabricated as previously described.9
Briefly, a silicon wafer was spin-coated with poly(methyl methacrylate)
(PMMA) followed by a baking step. The PMMA layer was spin-coated
with positive photoresist followed with another baking step. The wafer
was then exposed to UV light through a photomask to form the device
body features. The exposed wafer was developed and postbaked. The
PMMA surrounding the masked region was dry etched with oxygen
plasma in a Surface Technology PE1000 AC Plasma Source Reactive
Ion Etcher. Remaining photoresist was removed by incubation in pho-
toresist remover. To fabricate the reservoirs, the microdevice bodies
were spin-coated with photoresist followed by UV exposure through a
second photomask with a reservoir pattern aligned over the microde-
vice bodies. The microdevices were then developed and dry etched,
and excess photoresist was removed to form microdevices with reser-
voirs. The final microdevices were disc-shaped, 200 mm in diameter
and 8 mm in height. Each device contained a central reservoir 100 mm
in diameter and 5.5 mm in depth, corresponding to a volume of 43.2
pL. Each 3-inch silicon wafer contained a 4 3 4 array of 20 3 20
microdevice subarrays for a total device count of 6,400.
2.3 | Microdevice surface modification
Prior to drug printing, the silicon wafer with fabricated microdevices
was silanized with trichloro(1H,1H,2H,2H-perfluorooctyl)silane via
vapor deposition under vacuum at room temperature for 30 min.
Wafers were printed the same day as silanization.
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2.4 | Drug loading into microdevices
Drug printing was performed using the sciFLEXARRAYER S3 (Scienion
AG, Johannisthal, Germany) (Figure 1). This system is an automated
picoliter drop-on-demand piezoelectric printing system suitable for
deposition of 50-800 pL drops at up to 1000 Hz with positional accu-
racy of620 mm. The printer is composed of an XYZ movable head
with a mounted piezo-driven dispenser. Topotecan and insulin solu-
tions were prepared on the day of printing at 10 mg/mL in 10 mM HCl
and filtered through a 100 kDa centrifuge tube for 10 min at 5,000 rel-
ative centrifugal force. The freshly prepared drug solutions were then
loaded into a microtiter plate. Prior to printing, drug solution was aspi-
rated into the dispenser nozzle. During setup, the printer’s control unit
was aligned to the fiduciaries on the silicon wafer, which enabled pro-
grammable automatic dispensing. The printer is equipped with a cam-
era to visualize drop volume, stability, and trajectory, which can be
adjusted by changing the piezo voltage, pulse width, and frequency.
These parameters were optimized to obtain drops with volumes of
400 pL. Single 400 pL drops of either drug solution were printed into
device reservoirs at a rate of 400 devices per minute. The printing
process was performed in multiple cycles to allow the solvent to com-
pletely evaporate between each cycle, preventing solution spillover.
2.5 | Scanning electron microscopy
Samples were prepared for scanning electron microscopy (SEM) by
sputter coating with 8 nm of gold followed by mounting onto carbon
tape. The samples were imaged with a Carl Zeiss Ultra 55 field emis-
sion scanning electron microscope.
2.6 | Cellular toxicity studies
To determine the cytotoxicity of silanized microdevices, samples were
analyzed using a proliferation assay from the CyQUANT direct cell pro-
liferation assay kit. Prior to use, drug-loaded microdevices were stored
desiccated at 48C. Caco-2 cells were grown to confluency in 12-well
tissue culture plates. All media was aspirated from wells and one of the
following was added in triplicate: media containing 400 silanized and
FIGURE 1 nostripSchematic of printer configuration. Prior to each run, drug is drawn from the microtiter plate into the nozzle, and the
fiduciary markers on the wafer are recognized by automated recognition of images taken by the alignment camera. Drug is then printed
into microdevice reservoirs in an automated sequence. For each printing pass, the nozzle is dipped into the wash basin, and the drop
camera is used to confirm successful formation of 400 pL droplets for the specified piezo settings. The printer then dispenses a single
droplet into the reservoir of each microdevice on the wafer. Droplets quickly dry, and additional drug solution is printed over solidified drug
in future passes. Finally, the alignment camera captures quality-control images of all devices
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insulin-filled microdevices, media only, or 20% dimethyl sulfoxide in
media. Microdevices were scraped from the wafer with a razor and
added to the media. The microdevices sunk in the media to come into
direct contact with cells. The cells were then incubated at 378C, 5%
CO2 for 4 hrs. At the end of the incubation, cells were trypsinized and
spun down to pellets via centrifugation. Trypsinizing and pelleting the
cells allowed for collection of any cells that had lost adherence due to
death or damage, which increased the sensitivity of the assay. The
supernatant was discarded, and the cells were resuspended in PBS.
Detection reagent with background suppressor was then added to
each tube. The samples were incubated at 378C for one h and then
plated in a 96-well plate in triplicate. Fluorescence of samples was
measured using a spectrophotometer with cells in suspension.
2.7 | Insulin stability assay
Microdevices were printed with 12 layers of insulin as previously out-
lined and stored under desiccated conditions at 48C until stability anal-
ysis (within 1 week). Immediately before analysis, insulin was extracted
from two sub-arrays containing a total of 800 microdevices by incubat-
ing in 10 mL 0.1 N HCl at 48C for 1 hr. Samples were then analyzed
with reverse-phase high-pressure liquid chromatography (HPLC). For
each sample, 200 lL were injected into a 50 3 2 mm Proto 200 5 lm
C18 column (Higgins Analytical, USA.). A linear gradient from 30% to
35% 0.1% (vol/vol) trifluoroacetic acid (TFA) in water: 0.08% TFA in
acetonitrile was applied over 10 min at a flow rate of 0.7 mL/min. Insu-
lin and insulin degradation products were detected over time my meas-
uring UV absorbance at 214 nm. Insulin stability was calculated as the
ratio of the area of the known insulin peak to the total area of all
detected peaks.
3 | RESULTS AND DISCUSSION
Because planar microdevices can be used for oral delivery of both small
molecule drugs and biological therapeutics, drug loading techniques
will ideally be compatible with both small molecules and biologics in
addition to being compatible with techniques for microdevice fabrica-
tion. We chose topotecan, an inhibitor of DNA enzyme topoisomerase
I used as a chemotherapeutic, as a model small molecule drug.17,18
Orally administered chemotherapy could reduce hospital admissions or
visits to outpatient infusion centers for parenteral administration. How-
ever, oral formulations require higher amounts of drug to be delivered
compared to the intravenous route, which can lead to higher off-target
effects and toxicity. Preparing chemotherapeutic agents in microdevice
form can potentially reduce the dosage needed.
We sought to expand the utility of this platform by also examining
insulin as a model biologic. Insulin is an important peptide hormone
that is secreted by the beta cells in the Islets of Langerhans within the
pancreas to signal for cellular glucose uptake from the bloodstream.
Insulin is currently administered by multiple subcutaneous injections
per day or via insulin pumps. This is not ideal due to issues such as
noncompliance, cost, and tissue damage at injection sites. Oral delivery
of insulin is preferable as it is a less painful administrative route and
can reduce peripheral hyperinsulinemia. However, previous research
investigating insulin for oral drug delivery has not been able to translate
clinically due to its low stability and GI permeability.19,20 Microdevices
loaded with a high density of insulin may potentially overcome bioa-
vailability limitations.
The shape and size of the drug delivery vehicle are important
parameters to consider in oral drug delivery. We fabricated planar
microdevices 200 mm in diameter and 8 mm in height. This low aspect
ratio is necessary to resist shear flow from peristalsis and increase resi-
dence time. Each microdevice possesses an inner reservoir measuring
100 mm in diameter and 5.5 mm in depth. Furthermore, the reservoir is
etched into only one side of the device, allowing for unidirectional drug
release toward intestinal tissue and high local drug concentration at
the epithelium.
The ability to load relatively large amounts of drug with minimal
drug waste holds many advantages. The inkjet printer enables printing
of drug directly into the reservoir and obviates the need of other meth-
ods such as spin-casting or supercritical impregnation which can result
in significant drug loss and do not guarantee uniform loading
conditions.
Surface energy is an important consideration when spotting into
the shallow wells of microdevices. Before printing, the microdevices
were silanized via vapor deposition of trichloro(1H,1H,2H,2H-perfluor-
ooctyl)silane, a silane commonly used to render surfaces hydropho-
bic.21,22 The hydrophobic surface on the microdevices allowed printed
drops to collect inside the reservoir (Figure 2). When loading microde-
vices without the silane treatment, the drops would collect outside the
reservoir, which compromised loading efficiency. Following silane treat-
ment, the drops localized into the reservoir without overflow. Silanized
microdevices were used henceforth for topotecan and insulin loading.
Drug delivery systems must also display a favorable toxicological
profile in addition to demonstrating efficacy. Although we have tested
microdevices in animal models before, this is the first time we have uti-
lized silane deposition on microdevices. Silane in large quantities can
be toxic to cells. However, previous studies using silanized nanopar-
ticles did not show cell cytotoxicity suggesting the silanization process
uses volumes small enough to be biocompatible.23 Additionally, previ-
ous work in our lab has shown these planar microdevices to have no
effect on cell viability prior to drug loading.8 To confirm that silanized
microdevices do not cause cytotoxicity and are thus biocompatible, we
conducted a CyQUANT assay using Caco-2 cells, a heterogeneous
human epithelial colorectal adenocarcinoma cell line that is used as a
model for the GI tract.24 Here, we show that silanized, drug-loaded
microdevices do not significantly decrease live cell counts compared to
cells incubated in media alone (Figure 3). The DMSO group showed an
expected decrease in cell viability. Assuming all microdevices lie flat on
the cells, there is 38.1% coverage of the total area, which is much
higher than would be expected in vivo. Either side of the microdevice
could come into contact with the cells, so 50% of the microdevices
have their silanized surface in direct contact with the cells. The silane is
not cross-linked to the surface, but the cytoxicity data suggest that any
dissociation is not toxic at these levels. If toxicity is seen in the future,
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the silane could be cross-linked. The results indicate that the silanized,
drug loaded microdevices display negligible cytotoxicity, a necessary
feature when translating to animal models.
The microdevices are not biodegradable on the time scale antici-
pated for residence in the GI tract. These devices are expected to pass
completely and be excreted prior to any meaningful degradation. Addi-
tionally, the turnover time of the intestinal epithelium is 2-3 days.25
Even accounting for the expected increase in residence time of the
devices, they would shed with the epithelium and exit the body prior
to significant degradation.
As low-viscosity solutions (<10 cP) are most compatible with the
printer, we sought to find suitable solvents for both drugs. Topotecan
is soluble in aqueous solutions and is most stable at low pH values.26
Insulin is not soluble at neutral pH but increases solubility in acidic sol-
utions. Thus, we dissolved topotecan and insulin at 10 mg/mL in
10 mM HCl. The measured viscosity was found to be less than 10 cP
(data not shown). A silicon wafer with silanized microdevices was then
placed into the printer and aligned via image recognition of the fiducial
markers on the wafer before use.
Following loading of solution into the nozzle, the size of the topo-
tecan and insulin drops was tracked by the camera and software of the
printer. Before printing, 100 drops were dispensed at 200 Hz to calcu-
late the average volume. The average drop size was determined to be
400 pL. Camera images taken post-printing revealed that one 400 pL
drop was sufficient to fill the entirety of the microdevice reservoir
(Supporting Information Figure S1). When more than one drop was
printed at a time, we observed overflow beyond the reservoir. Thus,
one drop per microdevice was used during a single printing run. In
order to fill the entirety of the microdevice reservoir with dry, packed
drug, multiple runs were conducted with drying time between each
pass.
To determine the optimal number of single drops that can be
loaded into each microdevice, we systematically increased the number
of drops up to 16 total drops per microdevice and characterized load-
ing efficiency via SEM (Figure 4). For both topotecan and insulin, we
observed gradual filling of the reservoir with increasing cycles. Imaging
revealed that approximately 10 drops was the ideal number for loading
topotecan while 12 drops was ideal for insulin. Topotecan loading
beyond 10 drops began to overfill the microdevice reservoir until the
topotecan pellet delaminated from the reservoir. Insulin loading beyond
12 drops showed overflow, but no delamination was observed. The dif-
ferences in drug loading between topotecan and insulin are likely due
to the two drugs’ differing bulk densities.
Loading drug by printing 400 pL droplets in multiple passes
allowed for significantly higher loading capacity than previous loading
approaches utilizing spin casting and photolithography. For example,
spin-casting and UV-crosslinking a 10 mg/mL insulin hydrogel solution
to fill the 43.2 pL device reservoir volume would allow for loading of
0.432 ng of insulin per device. However, with inkjet printing, twelve
400 pL drops of 10 mg/mL insulin were printed into each device for a
FIGURE 3 Microdevice toxicity assay. In vitro CyQUANT viability
data showing that silane-coated microdevices do not show signifi-
cant toxicity to Caco-2 intestinal epithelial cells
FIGURE 2 nostripMicrodevice silanization enhances drug
localization into device reservoirs. (a) Fluorescence microscopy of
devices (outlined in green dashed lines) loaded with topotecan
(blue) indicates that drug spotting size was too large in
nonsilanized devices, with drug being deposited both inside device
reservoirs and onto the device body outside of the drug reservoirs.
(b) Devices silanized with trichloro(1H,1H,2H,2H-perfluoro-octly)
silane became more hydrophobic, providing efficient loading into
device reservoirs. Scale bars are 500 mm
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total of 48 ng insulin per device, a >100-fold increase in loading
capacity.
Topotecan is dosed based on body surface area and can be
expected to be delivered in the range of 1-4 mg/day given intrave-
nously. Oral dosing is given for specific clinical circumstances and is
threefold higher.27 Each microdevice contains 40 ng of topotecan, so
administering a maximum oral dose of 4 mg of topotecan would be
contained by 75,000 devices. Each 3-inch wafer contains 6,400 micro-
devices, thus approximately 15 wafers would contain the equivalent
dose. Insulin dosing is approximately 0.5-1 U/kg/day divided over 3 or
FIGURE 4 SEM images of topotecan and insulin printing. SEM images of representative microdevices loaded with increasing number of
400 pL drops of (a) 10 mg/mL topotecan and (b) 10 mg/mL insulin
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more subcutaneous injections.28 Thus, a 70-kg person could expect to
use 35-50 U/day (1.2-1.7 mg/day). Each microdevice contains 48 ng
of insulin, so administering a similar amount of drug would
be contained in 25,000-37,500 microdevices or approximately 4-6
wafers per day.
Drug stability following loading into microdevices is a concern, and
biological therapeutics such as insulin are more prone to degradation
than small molecule drugs due to their large molecular weight and com-
plexity.29 Therefore, reverse-phase HPLC was used to determine the
stability of insulin printed into microdevices (Supporting Information
Figure S2). Insulin stored in microdevices showed 21.560.3 mg per 20
3 20 array (of the expected 19.2 mg insulin). Differences in loading
may be caused by variations in droplet size during printing. Stability,
calculated as the ratio of the area of the known insulin peak to the
area of all peaks, was determined to be 96.060.6% after 28 days of
storage at 48C, indicating that the printing approach has a limited
impact on insulin integrity.
4 | CONCLUSION
In this work, we demonstrate the use of inkjet printing to efficiently
load two different drugs, topotecan and insulin, into microdevices.
The advantages of the inkjet printer system lie in its high-
throughput loading efficiency, accuracy, and programmability. Spot-
ting drug directly into the reservoir minimizes drug waste. Addition-
ally, multiple printing and drying cycles allow for significantly higher
drug loading capacity than that achieved by currently available tech-
niques limited to loading drug at its solubility limit. Furthermore, this
method does not require UV light or heat, which can damage sensi-
tive therapeutics, and measurements of the stability of printed insu-
lin demonstrate that biologics can be printed without significant
degradation. Surface functionalization increased surface hydropho-
bicity, which allowed printed drug solution to localize into microde-
vice reservoirs and did not show significant cytotoxicity. Future
studies will assess drug formulation and/or microdevice capping for
tunable drug release. This inkjet printing approach could be adapted
for low-waste, high capacity loading of a number of drugs into pla-
nar microdevices for oral drug delivery.
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